This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Carducci, M. A. Articles by Donehower, R. C. Search for Related Content PubMed PubMed Citation Articles by Carducci, M. A. Articles by Donehower, R. C.

A Phase I Clinical and Pharmacological Evaluation of Sodium Phenylbutyrate on an 120-h Infusion Schedule¹

Divisions of Medical Oncology [M. A. C., J. G., M. K. B., M. A. E., V. S., L. B. G., R. C. D.] and Experimental Therapeutics and Pharmacology [M. A. C., D. N., Y. Z., T-l. C., L. B. G.], The Johns Hopkins Oncology Center, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21231

Purpose: Sodium phenylbutyrate (PB) demonstrates potent differentiating capacity in multiple hematopoietic and solid tumor cell lines. We conducted a Phase I and pharmacokinetic study of PB by continuous infusion to characterize the maximum tolerated dose, toxicities, pharmacokinetics, and antitumor effects in patients with refractory solid tumors.

Patients and Methods: Patients were treated with a 120-h PB infusion every 21 days. The dose was escalated from 150 to 515 mg/kg/day. Pharmacokinetics were performed during and after the first infusion period using a validated high-performance liquid chromatographic assay and single compartmental pharmacokinetic model for PB and its principal metabolite, phenylacetate.

Results: A total of 24 patients were enrolled on study, with hormone refractory prostate cancer being the predominant tumor type. All patients were evaluable for toxicity and response. A total of 89 cycles were administered. The dose-limiting toxicity (DLT) was neuro-cortical, exemplified by excessive somnolence and confusion and accompanied by clinically significant hypokalemia, hyponatremia, and hyperuricemia. One patient at 515 mg/kg/day and another at 345 mg/kg/day experienced this DLT. Toxicity resolved 12 h of discontinuing the infusion. Other toxicities were mild, including fatigue and nausea. The maximum tolerated dose was 410 mg/kg/day for 5 days. Pharmacokinetics demonstrated that plasma clearance of PB increased in a continuous fashion beginning 24 h into the infusion. In individuals whose V_max for drug elimination was less than their drug-dosing rate, the active metabolite phenylacetate accumulated progressively. Plasma PB concentrations (at 410 mg/kg/day) remained above the targeted therapeutic threshold of 500 µmol/liter required for in vitro activity.

Conclusion: The DLT in this Phase I study for infusional PB given for 5 days every 21 days is neuro-cortical in nature. The recommended Phase II dose is 410 mg/kg/day for 120 h.

This article has been cited by other articles:

				S. Hauswald, J. Duque-Afonso, M. M. Wagner, F. M. Schertl, M. Lubbert, C. Peschel, U. Keller, and T. Licht Histone Deacetylase Inhibitors Induce a Very Broad, Pleiotropic Anticancer Drug Resistance Phenotype in Acute Myeloid Leukemia Cells by Modulation of Multiple ABC Transporter Genes Clin. Cancer Res., June 1, 2009; 15(11): 3705 - 3715. [Abstract] [Full Text] [PDF]

				S.-N. Kim, N. H. Kim, W. Lee, D.-W. Seo, and Y. K. Kim Histone Deacetylase Inhibitor Induction of P-Glycoprotein Transcription Requires Both Histone Deacetylase 1 Dissociation and Recruitment of CAAT/Enhancer Binding Protein {beta} and pCAF to the Promoter Region Mol. Cancer Res., May 1, 2009; 7(5): 735 - 744. [Abstract] [Full Text] [PDF]

				T. Hosoi, M. Sasaki, T. Miyahara, C. Hashimoto, S. Matsuo, M. Yoshii, and K. Ozawa Endoplasmic Reticulum Stress Induces Leptin Resistance Mol. Pharmacol., December 1, 2008; 74(6): 1610 - 1619. [Abstract] [Full Text] [PDF]

				G. S. Dow, Y. Chen, K. T. Andrews, D. Caridha, L. Gerena, M. Gettayacamin, J. Johnson, Q. Li, V. Melendez, N. Obaldia III, et al. Antimalarial Activity of Phenylthiazolyl-Bearing Hydroxamate-Based Histone Deacetylase Inhibitors Antimicrob. Agents Chemother., October 1, 2008; 52(10): 3467 - 3477. [Abstract] [Full Text] [PDF]

				N. L. Steele, J. A. Plumb, L. Vidal, J. Tjornelund, P. Knoblauch, A. Rasmussen, C. E. Ooi, P. Buhl-Jensen, R. Brown, T.R. J. Evans, et al. A Phase 1 Pharmacokinetic and Pharmacodynamic Study of the Histone Deacetylase Inhibitor Belinostat in Patients with Advanced Solid Tumors Clin. Cancer Res., February 1, 2008; 14(3): 804 - 810. [Abstract] [Full Text] [PDF]

				I. Gojo, A. Jiemjit, J. B. Trepel, A. Sparreboom, W. D. Figg, S. Rollins, M. L. Tidwell, J. Greer, E. J. Chung, M.-J. Lee, et al. Phase 1 and pharmacologic study of MS-275, a histone deacetylase inhibitor, in adults with refractory and relapsed acute leukemias Blood, April 1, 2007; 109(7): 2781 - 2790. [Abstract] [Full Text] [PDF]

				S. P. Perrine, O. Hermine, T. Small, F. Suarez, R. O'Reilly, F. Boulad, J. Fingeroth, M. Askin, A. Levy, S. J. Mentzer, et al. A phase 1/2 trial of arginine butyrate and ganciclovir in patients with Epstein-Barr virus-associated lymphoid malignancies Blood, March 15, 2007; 109(6): 2571 - 2578. [Abstract] [Full Text] [PDF]

				S. D. Gore, S. Baylin, E. Sugar, H. Carraway, C. B. Miller, M. Carducci, M. Grever, O. Galm, T. Dauses, J. E. Karp, et al. Combined DNA methyltransferase and histone deacetylase inhibition in the treatment of myeloid neoplasms. Cancer Res., June 15, 2006; 66(12): 6361 - 6369. [Abstract] [Full Text] [PDF]

				R. W. Robey, Z. Zhan, R. L. Piekarz, G. L. Kayastha, T. Fojo, and S. E. Bates Increased MDR1 Expression in Normal and Malignant Peripheral Blood Mononuclear Cells Obtained from Patients Receiving Depsipeptide (FR901228, FK228, NSC630176) Clin. Cancer Res., March 1, 2006; 12(5): 1547 - 1555. [Abstract] [Full Text] [PDF]

				H. I. Scher and C. L. Sawyers Biology of Progressive, Castration-Resistant Prostate Cancer: Directed Therapies Targeting the Androgen-Receptor Signaling Axis J. Clin. Oncol., November 10, 2005; 23(32): 8253 - 8261. [Abstract] [Full Text] [PDF]

				M. R. Acharya, A. Sparreboom, J. Venitz, and W. D. Figg Rational Development of Histone Deacetylase Inhibitors as Anticancer Agents: A Review Mol. Pharmacol., October 1, 2005; 68(4): 917 - 932. [Abstract] [Full Text] [PDF]

				K. Yamaguchi, A. Lantowski, A. J. Dannenberg, and K. Subbaramaiah Histone Deacetylase Inhibitors Suppress the Induction of c-Jun and Its Target Genes Including COX-2 J. Biol. Chem., September 23, 2005; 280(38): 32569 - 32577. [Abstract] [Full Text] [PDF]

				Q. C. Ryan, D. Headlee, M. Acharya, A. Sparreboom, J. B. Trepel, J. Ye, W. D. Figg, K. Hwang, E. J. Chung, A. Murgo, et al. Phase I and Pharmacokinetic Study of MS-275, a Histone Deacetylase Inhibitor, in Patients With Advanced and Refractory Solid Tumors or Lymphoma J. Clin. Oncol., June 10, 2005; 23(17): 3912 - 3922. [Abstract] [Full Text] [PDF]

				S. Phuphanich, S. D. Baker, S. A. Grossman, K. A. Carson, M. R. Gilbert, J. D. Fisher, and M. A. Carducci Oral sodium phenylbutyrate in patients with recurrent malignant gliomas: A dose escalation and pharmacologic study Neuro-oncol, April 1, 2005; 7(2): 177 - 182. [Abstract] [PDF]

				G. Gardian, S. E. Browne, D.-K. Choi, P. Klivenyi, J. Gregorio, J. K. Kubilus, H. Ryu, B. Langley, R. R. Ratan, R. J. Ferrante, et al. Neuroprotective Effects of Phenylbutyrate in the N171-82Q Transgenic Mouse Model of Huntington's Disease J. Biol. Chem., January 7, 2005; 280(1): 556 - 563. [Abstract] [Full Text] [PDF]

				X. Qi, T. Hosoi, Y. Okuma, M. Kaneko, and Y. Nomura Sodium 4-Phenylbutyrate Protects against Cerebral Ischemic Injury Mol. Pharmacol., October 1, 2004; 66(4): 899 - 908. [Abstract] [Full Text] [PDF]

				H. I Scher, G. Buchanan, W. Gerald, L. M Butler, and W. D Tilley Targeting the androgen receptor: improving outcomes for castration-resistant prostate cancer Endocr. Relat. Cancer, September 1, 2004; 11(3): 459 - 476. [Abstract] [Full Text] [PDF]

				J. Gilbert, S. D. Gore, J. G. Herman, and M. A. Carducci The Clinical Application of Targeting Cancer through Histone Acetylation and Hypomethylation Clin. Cancer Res., July 15, 2004; 10(14): 4589 - 4596. [Abstract] [Full Text] [PDF]

				M. Minamiyama, M. Katsuno, H. Adachi, M. Waza, C. Sang, Y. Kobayashi, F. Tanaka, M. Doyu, A. Inukai, and G. Sobue Sodium butyrate ameliorates phenotypic expression in a transgenic mouse model of spinal and bulbar muscular atrophy Hum. Mol. Genet., June 1, 2004; 13(11): 1183 - 1192. [Abstract] [Full Text] [PDF]

				Y. L. Chung, A.-J. Wang, and L.-F. Yao Antitumor histone deacetylase inhibitors suppress cutaneous radiation syndrome: Implications for increasing therapeutic gain in cancer radiotherapy Mol. Cancer Ther., March 1, 2004; 3(3): 317 - 325. [Abstract] [Full Text]

				T. Kasumov, L. L. Brunengraber, B. Comte, M. A. Puchowicz, K. Jobbins, K. Thomas, F. David, R. Kinman, S. Wehrli, W. Dahms, et al. NEW SECONDARY METABOLITES OF PHENYLBUTYRATE IN HUMANS AND RATS Drug Metab. Dispos., January 1, 2004; 32(1): 10 - 19. [Abstract] [Full Text] [PDF]

				Wm. K. Kelly, V. M. Richon, O. O'Connor, T. Curley, B. MacGregor-Curtelli, W. Tong, M. Klang, L. Schwartz, S. Richardson, E. Rosa, et al. Phase I Clinical Trial of Histone Deacetylase Inhibitor: Suberoylanilide Hydroxamic Acid Administered Intravenously Clin. Cancer Res., September 1, 2003; 9(10): 3578 - 3588. [Abstract] [Full Text] [PDF]

				J. A. Plumb, P. W. Finn, R. J. Williams, M. J. Bandara, M. R. Romero, C. J. Watkins, N. B. La Thangue, and R. Brown Pharmacodynamic Response and Inhibition of Growth of Human Tumor Xenografts by the Novel Histone Deacetylase Inhibitor PXD101 Mol. Cancer Ther., August 1, 2003; 2(8): 721 - 728. [Abstract] [Full Text] [PDF]

				C. Kennedy, K. Byth, C. L. Clarke, and A. deFazio Cell Proliferation in the Normal Mouse Mammary Gland and Inhibition by Phenylbutyrate Mol. Cancer Ther., October 1, 2002; 1(12): 1025 - 1033. [Abstract] [Full Text] [PDF]